GERMANTOWN, Md., Oct. 17 /PRNewswire-FirstCall/ -- MiddleBrook
Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on
developing and commercializing novel anti-infective products, today
announced that Lord Blyth of Rowington has been appointed vice chairman of
the board of directors effective Oct. 17, 2008. Lord Blyth has also been
retained as a consultant. In this capacity he will provide strategic
guidance in late-stage development and commercialization tactics.
Commenting on the appointment, MiddleBrook Chairman R. Gordon Douglas
said, "The board is delighted that James has assumed the vice chairman role
at MiddleBrook. His vast business experience will be invaluable as we build
the company into a commercial enterprise and work to create shareholder
value."
John Thievon, president and CEO, said, "I am extremely pleased to have
James join our board of directors as vice chairman, and I look forward to
working with him to ensure the future success of MiddleBrook."
Lord Blyth said, "It is an honor to join MiddleBrook's board of
directors at this pivotal stage of the company's development. I am excited
to work with my fellow directors and the company's management team to build
upon MiddleBrook's strong development foundation and help transform the
company into a commercial success."
Lord Blyth recently retired from his role as chairman of Diageo plc,
which he held since July 2000. Previously, he served as a non-executive
director at Diageo plc since January 1999. He was formerly chief executive
and then chairman of The Boots Company PLC. Lord Blyth has held several
leadership roles, including chief executive of the Plessey Company and head
of defense sales at the United Kingdom Ministry of Defense. He is also a
non-executive director of Anixter Inc. in the U.S. and a senior adviser to
Greenhill & Co Inc., where he was previously a vice chairman.
About Middlebrook Pharmaceuticals:
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical
company focused on the development and commercialization of anti-infective
drug products that fulfill substantial unmet medical needs in the treatment
of infectious disease. The Company is developing anti-infective drugs based
on its novel biological finding that bacteria exposed to antibiotics in
pulses are killed more efficiently than those under standard treatment
regimens. Based on this finding, MiddleBrook has developed a proprietary,
once-a-day pulsatile delivery technology called PULSYS(R). The Company
currently markets the KEFLEX(R) brand of cephalexin and has received
regulatory approval for MOXATAG(TM) -- the first and only once-daily
amoxicillin product approved for marketing in the U.S. For more on
MiddleBrook, please visit http://www.middlebrookpharma.com.
This announcement contains forward-looking statements, within the
meaning of the Securities Exchange Act of 1934 and the Securities Act of
1933, that involve risks and uncertainties. In some cases, forward-looking
statements are identified by words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and similar expressions. You
should not place undue reliance on these forward-looking statements, which
speak only as of the date of this announcement. All of these
forward-looking statements are based on information available to us at this
time, and we assume no obligation to update any of these statements. Actual
results could differ from those projected in these forward-looking
statements as a result of many factors, including those identified in the
sections titled "Risk Factors," "Management's Discussion and Analysis of
Financial Condition and Results of Operations" and elsewhere in our Annual
Report on Form 10-K for the year ended Dec. 31, 2007. We urge you to review
and consider the various disclosures made by us from time to time in our
filings with the Securities and Exchange Commission, that attempt to advise
you of the risks and factors that may affect our future results.
SOURCE MiddleBrook Pharmaceuticals, Inc.
 back to top
Related links:
http://www.middlebrookpharma.com
CONTACT:
Investors-Media, Faith Pomeroy-Ward of
MiddleBrook Pharmaceuticals, Inc., +1-301-944-6585
|
